Since 1973, two studies covering a 10-year period in the United States were conducted by the Commission on Cancer of the American College of Surgeons. Participating hospitals from over 1,200 institutions contributed over 70,000 cases to this report and review which represent nearly 80% of the newly diagnosed cancer cases in the United States annually at the present time. From these studies, certain confirmations of trends in the general treatment at the local level for prostate cancer were observed. For example, there was an overall reduction in the number of patients receiving hormone treatment for localized prostate cancer. Concurrently, more patients received external radiotherapy or surgery for the localized lesions. Disseminated newly diagnosed prostate cancer was equally treated by orchiectomy or diethylstilbestrol. A distinct relationship was observed between the grade of the tumor and the stage. In the latter 5-year period of this observation time, more patients were graded by pathologists upon diagnosis at their community hospital than previously. This exceeded over 85% and represented a remarkable conversion. The more frequent grading system used was that employed and described by Gleason. Ongoing studies from the National Prostatic Cancer Project reported through March 1987 have revealed some promising results in combinations of hormones and chemotherapy for newly diagnosed metastatic patients. The pattern of use of hormone therapy in the USA as judged by the national surveys is changing. In a recent study, Stilphostrol was found to be of some merit in treating hormone failures in metastatic prostate cancer as compared to Megace or streptozotocin.

Keywords:
Prostate cancer, Metastases, Hormones
This content is only available via PDF.
© 1988 S. Karger AG, Basel
1988
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.